Article
A single nucleotide polymorphism of reduced folate carrier 1 predicts methotrexate efficacy in Japanese patients with rheumatoid arthritis.
Drug metabolism and pharmacokinetics - 1 Jan 2013
Hayashi Hideki, Tazoe Yui, Tsuboi Seiji, Horino Masato, Morishita Mariko, Arai Teruhisa, Ohshima Motohiro, Matsuyama Taiji, Kosuge Kazuhiro, Yamada Hiroshi, Tsuji Daiki, Inoue Kazuyuki, Itoh Kunihiko
Abstract excerpt
Methotrexate (MTX) exhibits large inter-individual and inter-ethnic differences in the dose required for its anti-rheumatic effect. To maintain low disease activity, patients may require increased MTX doses or co-administration of biologic disease-modifying anti-rheumatic drugs (bDMARDs). The availability of a marker predicting the effect of MTX will make it possible to increase the MTX dose and prescribe bDMARDs...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
